Key result
Thromboprophylaxis with low molecular weight heparin and low-dose aspirin during pregnancy reduces the risk of thrombosis and adverse outcomes in women with inherited thrombophilia, whereas evidence for nattokinase remains limited.
Why the study?
Pulmonary embolism remains the leading cause of maternal mortality despite increasing LMWH use, but evidence for optimal thromboprophylaxis to prevent VTE and pregnancy complications in women with thrombophilia is scarce.
Does thromboprophylaxis (LMWH, aspirin, nattokinase) prevent adverse complications in pregnant women with inherited thrombophilia?
Does thromboprophylaxis (LMWH, aspirin, nattokinase) prevent adverse complications in pregnant women with inherited thrombophilia?
LMWH and aspirin are established prophylactic strategies to reduce VTE and adverse pregnancy outcomes in women with inherited thrombophilia, whereas alternative therapies like nattokinase lack sufficient evidence.
No takes yet. Share an insight, caveat, or question.
Scarce evidence on thromboprophylaxis leaves optimal strategies undefined in high-risk pregnancies; prospective trials needed before practice change.
Kirovakov et al. (2024) conducted a review in Inherited thrombophilia in pregnancy. Thromboprophylaxis (Low Molecular Weight Heparin, Aspirin, Nattokinase) was evaluated. Thromboprophylaxis with low molecular weight heparin and low-dose aspirin during pregnancy reduces the risk of thrombosis and adverse outcomes in women with inherited thrombophilia, whereas evidence for nattokinase remains limited.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: